Emily R W Davidson1, Lia Miceli1, Katie Propst1. 1. Center for Urogynecology and Pelvic Reconstructive Surgery, Obstetrics, Gynecology and Women's Health Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Abstract
Objective: Despite an established treatment algorithm for overactive bladder (OAB), it is unclear how many patients proceed through each step. Our objective was to evaluate the percentage of patients receiving each step of care and identify reasons why patients did not receive certain treatments. Methods: This was a retrospective cohort study with cross-sectional survey of new OAB patients. The medical record was queried for relevant patient characteristics and documentation of conservative, medical, and third-line therapies. In the survey, patients were asked about current bladder symptoms and reasons why they did not use certain treatments. Descriptive statistics were used for analysis. Results: One hundred eleven patients met the inclusion criteria; the most common diagnosis was mixed incontinence (40%, n = 45). The median number of visits for OAB was 2 (range 1-8). On retrospective analysis, 64% (71) of patients had documented attempts at conservative therapy. Seventy-six percent (84) of patients attempted medical therapy, and only 11% (12) progressed to any third-line therapy. Fifty-nine percent (64) of eligible patients responded to the survey. Fifty-three percent (34) of respondents reported persistent moderate to very severe bother due to bladder symptoms. Thirty percent to fifty percent of patients who did not attempt one or more of the three levels of OAB therapy reported that they were never offered that treatment option. Conclusions: Many patients do not progress to the next steps in OAB therapy despite failure of more conservative treatments. Barriers to care included limited follow-up and education about other therapy options. A formalized institutional care pathway may lead to improved OAB treatment.
Objective: Despite an established treatment algorithm for overactive bladder (OAB), it is unclear how many patients proceed through each step. Our objective was to evaluate the percentage of patients receiving each step of care and identify reasons why patients did not receive certain treatments. Methods: This was a retrospective cohort study with cross-sectional survey of new OAB patients. The medical record was queried for relevant patient characteristics and documentation of conservative, medical, and third-line therapies. In the survey, patients were asked about current bladder symptoms and reasons why they did not use certain treatments. Descriptive statistics were used for analysis. Results: One hundred eleven patients met the inclusion criteria; the most common diagnosis was mixed incontinence (40%, n = 45). The median number of visits for OAB was 2 (range 1-8). On retrospective analysis, 64% (71) of patients had documented attempts at conservative therapy. Seventy-six percent (84) of patients attempted medical therapy, and only 11% (12) progressed to any third-line therapy. Fifty-nine percent (64) of eligible patients responded to the survey. Fifty-three percent (34) of respondents reported persistent moderate to very severe bother due to bladder symptoms. Thirty percent to fifty percent of patients who did not attempt one or more of the three levels of OAB therapy reported that they were never offered that treatment option. Conclusions: Many patients do not progress to the next steps in OAB therapy despite failure of more conservative treatments. Barriers to care included limited follow-up and education about other therapy options. A formalized institutional care pathway may lead to improved OAB treatment.
Entities:
Keywords:
delivery of health care; lower urinary tract symptoms; nocturia; overactive; urge; urinary bladder; urinary incontinence
Authors: Desiree Vrijens; Jamie Drossaerts; Gommert van Koeveringe; Philip Van Kerrebroeck; Jim van Os; Carsten Leue Journal: J Psychosom Res Date: 2014-11-27 Impact factor: 3.006
Authors: Chris Du; William T Berg; Alexandra R Siegal; Zhenyue Huang; Anh Nguyen; Alice Cheung; Sina Mehraban-Far; Rebecca Anderson; Sophia Jacob; Jason Kim Journal: Neurourol Urodyn Date: 2020-11-16 Impact factor: 2.696
Authors: Heidi W Brown; Emilie J Braun; Meg E Wise; Shannon Myers; Zhanhai Li; Emmanuel Sampene; Sierra M Jansen; D Paul Moberg; Jane E Mahoney; Rebecca G Rogers Journal: Obstet Gynecol Date: 2019-09 Impact factor: 7.623
Authors: Gabriela Gonzalez; Kristina Vaculik; Carine Khalil; Yuliya Zektser; Corey W Arnold; Christopher V Almario; Brennan M R Spiegel; Jennifer T Anger Journal: Int Urogynecol J Date: 2021-03-12 Impact factor: 1.932